Adjusted operating expenses increased 12% operationally, with SG&A growth of 11% operationally, driven by headcount-related compensation costs as a result of our U.S. small animal field force expansion, which largely began in Q2 of 2022, and higher T&E.

May 4, 2023 / receipt, needs a key / Wetni Joseph, CFO | earnings call 2023-05-04 | transcript c57f5629-1655-45e8-9d6b-307614c72b54 | chars 17474-17727 | segment 17

Adjusted operating expenses increased 3% operationally, with SG&A growth of 3% operationally, driven by T&E costs beginning to return to pre-COVID levels, as well as freight and logistics.

Nov 3, 2022 / receipt, needs a key / Wetney Joseph, CFO | earnings call 2022-11-03 | transcript e1c8cb9d-b36e-4a79-b6e0-6645cd65afa7 | chars 18897-19085 | segment 19

Adjusted operating expense increased 10% operationally, with SG&A growth of 8% operationally, driven by promotional and marketing expenses related to key brands and new product launches, as well as T&E costs beginning to return to pre-COVID levels.

Aug 4, 2022 / receipt, needs a key / Whitney Joseph, CFO | earnings call 2022-08-04 | transcript b216c6da-710b-46aa-8f96-d05401d1f3b3 | chars 19100-19348 | segment 19

Adjusted operating expenses increased 14% operationally, with SG&A growth of 16% operationally, driven by headcount related compensation costs, T&E, advertising and promotion, as well as direct to pet owner campaigns for key brands.

May 5, 2022 / receipt, needs a key / CEO, CEO | earnings call 2022-05-05 | transcript 5f28cfbe-5fd7-4cf5-974d-0dc2f9b0447c | chars 19849-20081 | segment 20

Adjusted operating expenses increased 19% operationally, with SG&A expenses growing 20% operationally, resulting from increased compensation related costs, as well as increased advertising and promotion expense, freight, and T&E.

Nov 4, 2021 / receipt, needs a key / Wetni, CFO | earnings call 2021-11-04 | transcript 571809f9-9097-42aa-945a-f9a25bbbb383 | chars 20533-20762 | segment 20

This was partially offset by reductions to T&E costs as a result of COVID-19.

May 6, 2021 / receipt, needs a key / CEO, CEO | earnings call 2021-05-06 | transcript 4679e981-c6e5-45d0-aaaa-9e6c4fdcd26e | chars 21216-21293 | segment 21

We would expect that T&E expenditures would begin to increase, particularly in the second half of the year, but also our compensation costs.

May 6, 2021 / receipt, needs a key / Glenn Stevens, CFO | earnings call 2021-05-06 | transcript 4679e981-c6e5-45d0-aaaa-9e6c4fdcd26e | chars 44481-44621 | segment 44

Adjusted operating expenses increased 10% operationally, resulting from increased advertising and promotion expenses from Caracatrio and Applequell, partially offset by T&E savings.

Feb 16, 2021 / receipt, needs a key / CFO, CFO | earnings call 2021-02-16 | transcript 2c942fd4-090b-46b0-85bb-3a47af256a64 | chars 18397-18578 | segment 18

Yeah, Mike, in terms of the increased spending in the quarter, as you mentioned, we did increase spending in Q3 with total OPEX up about 9% and SG&A up 11%. And really what we did there is we took a lot of the savings that we saw from T&E and made incremental investment behind some of our key growth brands, particularly some Paracatrio and Applequo, in the tune of DTC advertising, which was even greater than the savings that we saw from a T&E perspective, because we believe those are the right investments, and we're seeing a very strong return on those to support the future growth of the brands.

Nov 6, 2020 / receipt, needs a key / Glenn (likely Glenn Steiger, CFO), CFO | earnings call 2020-11-06 | transcript 2de18ac1-f3c8-4255-877c-b33536a715c7 | chars 28520-29122 | segment 28

We have strategically reallocated savings, mainly from T&E costs, into these high-return promotional programs, which have been successful in increasing sales.

Nov 6, 2020 / receipt, needs a key / Glenn (CEO), CEO | earnings call 2020-11-06 | transcript 2de18ac1-f3c8-4255-877c-b33536a715c7 | chars 17575-17733 | segment 17

The incremental advertising and promotion expenses related to Simparica TRIO Recent acquisitions and R&D increases were largely offset by reductions to T&E and compensated related costs as a result of COVID-19.

Aug 6, 2020 / receipt, needs a key / Kristen Chominski, CFO | earnings call 2020-08-06 | transcript b6cd160c-32d7-4109-89f8-6a90f6d435fe | chars 18152-18362 | segment 18

As we move into the second half of the year and our field returns more and more to visiting clinics, T&E expenses, which has been very favorable, particularly in Q2, will rise as we go into Q3 and Q4.

Aug 6, 2020 / receipt, needs a key / Ed, other | earnings call 2020-08-06 | transcript b6cd160c-32d7-4109-89f8-6a90f6d435fe | chars 24472-24672 | segment 24

disciplined cost management

ir_statement / Sep 16, 2026 / receipt

Organic Operational Growth2 (3)% - (1)% Revenue

ir_statement / Sep 16, 2026 / receipt

Adjusted R&D expenses2 $720 to $730

ir_statement / Sep 16, 2026 / receipt

Adjusted SG&A expenses2 $2,330 to $2,380

ir_statement / Sep 16, 2026 / receipt

Based on softer end-market, macro-driven sensitivity, and promotion-led competitive pressure

ir_statement / Sep 16, 2026 / receipt

Continued advancing the portfolio and expanding market access, including the VitalRADS acquisition, commercial launches of Lenivia® and Portela in the EU and Canada and approvals in Great Britain

ir_statement / Sep 16, 2026 / receipt

Revised FY'26 guidance, reflecting persistence of market conditions and the actions we are taking in response

ir_statement / Sep 16, 2026 / receipt

Accelerated commercial launches of Lenivia and Portela in Canada and Europe, driven by encouraging early experience

ir_statement / Sep 16, 2026 / receipt

Appointed new U.S. Commercial Leadership

ir_statement / Sep 16, 2026 / receipt

Delivering against enterprise cost and productivity program to drive operating efficiencies

ir_statement / Sep 16, 2026 / receipt

Reallocated A&P to highest-ROI programs

ir_statement / Sep 16, 2026 / receipt

Increasing targeted sales, marketing, and gross-to-net investments and reinforcing the portfolio's differentiated value

ir_statement / Sep 16, 2026 / receipt